A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

Yiyun Wang; Yingying Yang; Ruimin Hong; Houli Zhao; Guoqing Wei; Wenjun Wu; Huijun Xu; Jiazhen Cui; Yanlei Zhang; Alex H Chang; Yongxian Hu; He Huang

doi:10.1038/s41408-020-00371-6

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Cancer J. 2020 Oct 19;10(10):105. doi: 10.1038/s41408-020-00371-6.

Authors

Yiyun Wang^{1

2

3

4}, Yingying Yang^{1

2

3

4}, Ruimin Hong^{1

2

3

4}, Houli Zhao^{1

2

3

4}, Guoqing Wei^{1

2

3

4}, Wenjun Wu^{1

2

3

4}, Huijun Xu^{1

2

3

4}, Jiazhen Cui^{1

2

3

4}, Yanlei Zhang⁵, Alex H Chang⁵, Yongxian Hu^{6

7

8

9}, He Huang^{10

11

12

13}

Affiliations

¹ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China.
² Institute of Hematology, Zhejiang University, Zhejiang, China.
³ Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang, China.
⁴ Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Zhejiang, China.
⁵ Shanghai YaKe Biotechnology Ltd, Shanghai, China.
⁶ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China. 1313016@zju.edu.cn.
⁷ Institute of Hematology, Zhejiang University, Zhejiang, China. 1313016@zju.edu.cn.
⁸ Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang, China. 1313016@zju.edu.cn.
⁹ Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Zhejiang, China. 1313016@zju.edu.cn.
¹⁰ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China. huanghe@zju.edu.cn.
¹¹ Institute of Hematology, Zhejiang University, Zhejiang, China. huanghe@zju.edu.cn.
¹² Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang, China. huanghe@zju.edu.cn.
¹³ Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Zhejiang, China. huanghe@zju.edu.cn.

No abstract available

Publication types

Clinical Trial
Comparative Study
Letter

MeSH terms

Antigens, CD19*
Female
Humans
Immunotherapy, Adoptive*
Male
Neoplasm Proteins*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Retrospective Studies
Sialic Acid Binding Ig-like Lectin 2*

Substances

Antigens, CD19
CD22 protein, human
Neoplasm Proteins
Sialic Acid Binding Ig-like Lectin 2